$11.39
1.81% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$11.39
+0.63 5.86% 1M
-0.41 3.47% 6M
-0.44 3.72% YTD
+0.82 7.76% 1Y
+6.71 143.38% 3Y
+1.47 14.82% 5Y
+1.47 14.82% 10Y
+1.47 14.82% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.21 1.81%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Basic
Market capitalization
$7.7b
Enterprise Value
$2.9b
Net debt
$-4.9b
Cash
$4.9b
Shares outstanding
695.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
266.54 | 259.65
EV/Sales
98.32 | 95.77
EV/FCF
negative
P/B
1.69
Financial Health
Equity Ratio
86.22%
Return on Equity
-3.67%
ROCE
-21.06%
ROIC
-227.22%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$29.1m | $29.8m
EBITDA
$-1.1b | $-1.3b
EBIT
$-1.1b
Net Income
$-172.0m | $-912.2m
Free Cash Flow
$-844.1m
Growth (TTM | estimate)
Revenue
-76.72% | 2.65%
EBITDA
-1.41% | -16.55%
EBIT
-0.66%
Net Income
-103.95% | -430.39%
Free Cash Flow
-10.10%
Margin (TTM | estimate)
Gross
96.86%
EBITDA
-3,784.84% | -4,297.74%
EBIT
-3,833.27%
Net
-591.96% | -3,058.81%
Free Cash Flow
-2,905.21%
More
EPS
$-0.24
FCF per Share
$-1.21
Short interest
9.05%
Employees
908.00
Rev per Employee
$30.00k
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Roivant Sciences forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a Roivant Sciences forecast:

Buy
88%
Hold
13%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
29 29
77% 77%
100%
- Direct Costs 0.91 0.91
94% 94%
3%
28 28
74% 74%
97%
- Selling and Administrative Expenses 591 591
14% 14%
2,036%
- Research and Development Expense 550 550
4% 4%
1,895%
-1,100 -1,100
1% 1%
-3,785%
- Depreciation and Amortization 14 14
36% 36%
48%
EBIT (Operating Income) EBIT -1,114 -1,114
1% 1%
-3,834%
Net Profit -172 -172
104% 104%
-592%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
GlobeNewsWire
12 days ago
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects
Neutral
GlobeNewsWire
19 days ago
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.
Neutral
Seeking Alpha
30 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci...
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today